---
title: "Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290050004.md"
description: "U.S. stock futures rose, but several stocks declined in pre-market trading. Sophia Genetics fell after pricing a $50M public offering. Ormat Technologies dropped 6.1% following an Underperform rating from Bernstein. Other decliners included Liberty Latin America, Veraxa Biotech, and Corecivic."
datetime: "2026-06-17T12:03:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290050004.md)
  - [en](https://longbridge.com/en/news/290050004.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290050004.md)
---

# Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining over 100 points on Wednesday.

Shares of **Sophia Genetics SA** (NASDAQ:SOPH) fell sharply in pre-market trading.

Sophia Genetics priced its underwritten public offering of 10.526 million ordinary shares at $4.75 each, raising gross proceeds of $50 million.

Sophia Genetics shares dipped 3.5% to $4.76 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

-   **Liberty Latin America Ltd** (NASDAQ:LILA) fell 26.7% to $5.71 in pre-market trading.
-   **Veraxa Biotech AG** (NASDAQ:VRXA) fell 12.4% to $8.29 in pre-market trading after declining 59% on Tuesday.
-   **SL Science Holding Ltd** (NASDAQ:SLBT) declined 10.4% to $7.95 in pre-market trading after surging 167% on Tuesday.
-   **Ormat Technologies, Inc.** (NYSE:ORA) shares fell 6.1% to $125.77 in pre-market trading. Bernstein analyst Sunaina Ocalan initiated coverage on Ormat Technologies with an Underperform rating and announced a price target of $115.
-   **Corecivic Inc** (NYSE:CXW) shares declined 5.8% to $26.27 in pre-market trading.
-   **Qualys Inc** (NASDAQ:QLYS) shares dipped 5.6% to $107.26 in pre-market trading.
-   **Lionsgate Studios Corp** (NYSE:LION) fell 4.7% to $15.60 in pre-market trading after jumping 14% on Tuesday.
-   **Silence Therapeutics PLC – ADR** (NASDAQ:SLN) declined 4.6% to $6.40 in pre-market trading. HC Wainwright & Co. analyst Patrick R. Trucchio reiterated Silence Therapeutics with a Buy and maintained a $75 price target.
-   **Sable Offshore Corp** (NYSE:SOC) fell 4.4% to $9.55 in pre-market trading after declining around 6% on Tuesday. The company announced the launch of a proposed senior secured term loan facility in an aggregate principal amount of up to $1 billion.
-   **Taysha Gene Therapies Inc** (NASDAQ:TSHA) fell 4.3% to $5.60 in pre-market trading.
-   **Solid Biosciences Inc** (NASDAQ:SLDB) declined 4.2% to $6.77 in pre-market trading.

_Photo via Shutterstock_

### Related Stocks

- [LILAK.US](https://longbridge.com/en/quote/LILAK.US.md)
- [SOPH.US](https://longbridge.com/en/quote/SOPH.US.md)
- [ORA.US](https://longbridge.com/en/quote/ORA.US.md)
- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)
- [LILA.US](https://longbridge.com/en/quote/LILA.US.md)
- [CXW.US](https://longbridge.com/en/quote/CXW.US.md)
- [SLBT.US](https://longbridge.com/en/quote/SLBT.US.md)
- [QLYS.US](https://longbridge.com/en/quote/QLYS.US.md)
- [LION.US](https://longbridge.com/en/quote/LION.US.md)
- [SLN.US](https://longbridge.com/en/quote/SLN.US.md)
- [SOC.US](https://longbridge.com/en/quote/SOC.US.md)
- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)
- [SLDB.US](https://longbridge.com/en/quote/SLDB.US.md)

## Related News & Research

- [Amundi Has $51.23 Million Stock Position in Ormat Technologies, Inc. $ORA](https://longbridge.com/en/news/294652784.md)
- [CoreCivic Chief Administrative Officer Cole G. Carter disposes of 12,500 common shares for $371,750](https://longbridge.com/en/news/294736953.md)
- [The memory crash has 4 big stocks down 30% or more from their highs. I'd buy 2 of them](https://longbridge.com/en/news/294276373.md)
- [$1000 Invested In Vanguard Morningstar Mega Cap Growth ETF 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/294711672.md)
- [Veraxa Biotech files first BiTAC-related patent applications for cancer therapy platforms](https://longbridge.com/en/news/294550628.md)